Lansons has worked closely with International Biotechnology Trust plc for over a decade, raising its profile amongst retail investors, intermediaries and wealth managers through a targeted media and analyst relations programme. The key objectives are to support the Trust’s strategy to further grow, communicate its key differentiators, support its financial results, and help bolster the investment case for biotech.
We have been achieving these objectives by securing key, sought after profiles and share tips columns in the nationals [Tempus, The Times circulation – 450,064; unique monthly browsers: 810,961; Fund Focus, Mail on Sunday – circulation: 1,328,581; unique monthly browsers: 27,000,000].
We have positioned the investment managers as key commentators through a regular stream of thought-leadership articles. We have continued to effectively target analysts. In addition, we have advised on marketing materials such as factsheets, the website and social media channels. The programme also supports the Trust’s announcements.
When introducing a dividend policy, our strategy was to proactively brief the media, highlighting the benefits to existing shareholders and potential investors. This resulted in positive coverage in ‘Investment Trust bargain of the week’ in the Sunday Telegraph [circulation 458,272] and intermediary trade publications.
We have continued to leverage the dividend story as part of the programme. Overall, the media and analyst sentiment towards the Trust remains extremely positive.
Working at a senior corporate level and across the institutional and retail business for one of world’s top asset managers
Repositioning Synergy Health as a partner of the health service through a public affairs engagement programme targeting politicians and NHS Trusts
Get in touch with our experts today.